Aethlon Medical, Inc. (NASDAQ:AEMD) – Investment analysts at Zacks Investment Research boosted their FY2018 EPS estimates for Aethlon Medical in a research note issued to investors on Wednesday. Zacks Investment Research analyst B. Marckx now anticipates that the medical equipment provider will earn ($0.56) per share for the year, up from their prior estimate of ($0.57).
Aethlon Medical (NASDAQ:AEMD) last released its earnings results on Thursday, November 2nd. The medical equipment provider reported ($0.14) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.16) by $0.02.
Separately, ValuEngine upgraded shares of Aethlon Medical from a “strong sell” rating to a “sell” rating in a report on Friday, September 1st.
Aethlon Medical (AEMD) traded up $0.03 during trading on Monday, reaching $0.95. 163,300 shares of the company’s stock were exchanged, compared to its average volume of 198,650. Aethlon Medical has a 12 month low of $0.79 and a 12 month high of $5.17. The company has a current ratio of 2.97, a quick ratio of 2.97 and a debt-to-equity ratio of 78.00.
Aethlon Medical Company Profile
Aethlon Medical, Inc is a medical device company focused on creating devices for cancer, infectious disease and other life-threatening conditions. The Company operates through two segments: Aethlon, which represents its therapeutic business activities, and ESI, which represents its diagnostic business activities.
Receive News & Ratings for Aethlon Medical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aethlon Medical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.